Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 ...

The company on Wednesday said that a Phase 1 trial for a subcutaneous formulation of ublituximab, the active agent in its Briumvi drug, was well-tolerated and achieved sustained drug exposure. The ...

Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session ...

TG Therapeutics (TGTX) stock jumps as the company announces Phase 1 data supporting an injectable Briumvi therapy for ...

TG Therapeutics said its phase 1 study of subcutaneous Briumvi generated data that support the quarterly dosing regimen now ...

All three suspects have admitted to selling the drug in violation of the pharmaceutical and medical devices law, ...

New BCMA-targeted bispecific antibody addresses critical unmet need in India, offering deep and durable responses for heavily ...

The bispecific antibody therapy works by activating the body’s immune system to attack cancer cells, binding simultaneously ...

Shares of TG Therapeutics Inc TGTX are climbing Wednesday afternoon following the release of early-stage clinical trial data for a new formulation of its multiple sclerosis drug, BRIUMVI. Here’s what ...

The U.S. cattle industry has not faced the threat of NWS for more than 60 years. The NWS fly, about the size of a common housefly, has migrated across Central America from Panama through Mexico and ...

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in ...

On 5 June 2026, an HIV prevention injection will for the first time become available at some of South Africa’s public sector ...